Catalog No.: PC-22941Not For Human Use, Lab Use Only.
Abimufloxacin (OPS-2071) is a novel quinolone antibacterial agent with potent antibacterial activity against 54 clinically isolated C. difficile strains with MIC50 of 0.125 ug/mL, reduces the risk of adverse events typical of fluoroquinolone class antibiotics.
Abimufloxacin (OPS-2071) is a novel quinolone antibacterial agent with potent antibacterial activity against 54 clinically isolated C. difficile strains with MIC50 of 0.125 ug/mL, reduces the risk of adverse events typical of fluoroquinolone class antibiotics.
OPS-2071 is more active than vancomycin on a concentration basis (MIC50, 2 μg/ml; MIC90, 4 μg/ml) and comparable to fidaxomicin (MIC50, 0.063 μg/ml; MIC90, 8 μg/ml).
OPS-2071 shows equally potent antibacterial activity against both hypervirulent and nonhypervirulent strains.
OPS-2071 shows significant in vivo efficacy at 0.0313 mg/kg/day (50% effective doses), 39.0-fold and 52.1-fold lower than those of vancomycin and fidaxomicin, respectively, in a hamster model of C. difficile infection.
